NCT01406639: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
|
|
| Withdrawn | 1 | 0 | US | Ranibizumab, Lucentis | University of California, San Diego, Genentech, Inc. | Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | 05/12 | 05/12 | | |
